IBEX 35
11.314,20 -14,80 (-0,13%) Euro Stoxx 50
5.043,87 +18,70 (+0,37%) Dólar/Euro
1,0848 +0,0021 (+0,20%) Petróleo Brent
82,55 +0,65 (+0,79%) Oro
2.368,60 -24,30 (-1,02%) Bitcoin EUR
64.169,47 -520,41 (-0,80%)
Jeil Pharma Holdings Inc (002620.KS)
Jeil Pharma Holdings Inc
343, Sapyeong-daero
Seocho-gu
Seoul 06543
South Korea
82 2 549 7451
https://www.jeilpharm.co.kr
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Seung-Soo Han | Chairman of The Board and Chief Executive Officer | N/A | N/A | 1947 |
Descripción
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Gobierno corporativo
El ISS Governance QualityScore de Jeil Pharma Holdings Inc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
